939043-31-9Relevant academic research and scientific papers
HETEROARYL COMPOUNDS AND USES THEREOF
-
, (2016/06/28)
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.
The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
Watson, Nigel S.,Adams, Carl,Belton, David,Brown, David,Burns-Kurtis, Cynthia L.,Chaudry, Laiq,Chan, Chuen,Convery, Máire A.,Davies, David E.,Exall, Anne M.,Harling, John D.,Irvine, Stephanie,Irving, Wendy R.,Kleanthous, Savvas,McLay, Iain M.,Pateman, Anthony J.,Patikis, Angela N.,Roethke, Theresa J.,Senger, Stefan,Stelman, Gary J.,Toomey, John R.,West, Robert I.,Whittaker, Caroline,Zhou, Ping,Young, Robert J.
, p. 1588 - 1592 (2011/05/05)
The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the form
1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors
-
Page/Page column 14, (2009/01/20)
The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds
